Abrysvo Data In Younger Adults Could Give Pfizer An Edge Over GSK

 
• By Jessica Merrill

Pfizer plans to use the positive Phase III data in adults 18-59 to expand use of the RSV vaccine.

RSV
Pfizer announced positive Phase III data for its RSV vaccine Abrysvo. • Source: Shutterstock

More from Anti-infective

More from Therapy Areas